5-12 However, in clinical trials, including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, participants were permitted to remain on a given dose for up to 4 additional weeks, as needed, to allow for the dissipation of any GI AEs
Instead of pushing to the full weight-loss dose, some patients start at a low dose, just enough to nudge the metabolic and inflammatory pathways, without major appetite suppression
If GLP-1 medications reduce these risks, even partially, the implications for long-term lupus management are profound
*prices subject to change
Allergic reaction: Symptoms include swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, or a rapid heartbeat